Bradley J. Bolzon PhD - Jun 28, 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Director
Signature
/s/ Robin L. Praeger, attorney-in-fact for Bradley Bolzon
Stock symbol
CRSP
Transactions as of
Jun 28, 2021
Transactions value $
-$7,106,341
Form type
4
Date filed
6/30/2021, 06:41 PM
Previous filing
Jun 23, 2021
Next filing
Jul 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Other $0 -616K -85.44% $0.00 105K Jun 28, 2021 See Footnote F1, F2
transaction CRSP Common Shares Other $0 +159K $0.00 159K Jun 28, 2021 See Footnote F3, F4
transaction CRSP Common Shares Other $0 -159K -100% $0.00* 0 Jun 28, 2021 See Footnote F4, F5
transaction CRSP Common Shares Other $0 +27.7K $0.00 27.7K Jun 28, 2021 Direct F6
transaction CRSP Common Shares Other $0 -3.65K -85.44% $0.00 622 Jun 28, 2021 See Footnote F7, F8
transaction CRSP Common Shares Other $0 -366K -62.9% $0.00 216K Jun 28, 2021 See Footnote F9, F10
transaction CRSP Common Shares Other $0 +79.1K $0.00 79.1K Jun 28, 2021 See Footnote F11, F12
transaction CRSP Common Shares Other $0 -11K -66.23% $0.00 5.61K Jun 28, 2021 See Footnote F13, F14
transaction CRSP Common Shares Other $0 +2.38K +3.01% $0.00 81.5K Jun 28, 2021 See Footnote F12, F15
transaction CRSP Common Shares Other $0 -12.2K -66.04% $0.00 6.27K Jun 28, 2021 See Footnote F16, F17
transaction CRSP Common Shares Other $0 +2.63K +3.23% $0.00 84.1K Jun 28, 2021 See Footnote F12, F18
transaction CRSP Common Shares Other $0 -84.1K -100% $0.00* 0 Jun 28, 2021 See Footnote F12, F19
transaction CRSP Common Shares Other $0 +19K +68.46% $0.00 46.7K Jun 28, 2021 Direct F20
transaction CRSP Common Shares Other $0 -27.9K -62.9% $0.00 16.4K Jun 28, 2021 See Footnote F21, F22
transaction CRSP Common Shares Other $0 +6.02K $0.00 6.02K Jun 28, 2021 See Footnote F23, F24
transaction CRSP Common Shares Other $0 -6.02K -100% $0.00* 0 Jun 28, 2021 See Footnote F24, F25
transaction CRSP Common Shares Other $0 +847 +1.81% $0.00 47.5K Jun 28, 2021 Direct F26
transaction CRSP Common Shares Sale -$204K -1.4K -2.95% $145.92 46.1K Jun 29, 2021 Direct F27, F28
transaction CRSP Common Shares Sale -$88K -600 -1.3% $146.69 45.5K Jun 29, 2021 Direct F27, F29
transaction CRSP Common Shares Sale -$705K -4.78K -10.5% $147.43 40.8K Jun 29, 2021 Direct F27, F30
transaction CRSP Common Shares Sale -$1.81M -12.2K -29.88% $148.58 28.6K Jun 29, 2021 Direct F27, F31
transaction CRSP Common Shares Sale -$1.19M -7.98K -27.93% $149.47 20.6K Jun 29, 2021 Direct F27, F32
transaction CRSP Common Shares Sale -$1.92M -12.8K -61.91% $150.49 7.85K Jun 29, 2021 Direct F27, F33
transaction CRSP Common Shares Sale -$1.01M -6.65K -84.71% $151.24 1.2K Jun 29, 2021 Direct F27, F34
transaction CRSP Common Shares Sale -$183K -1.2K -100% $152.42 0 Jun 29, 2021 Direct F27, F35
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV") to its partners pursuant to a Rule 10b5-1 trading plan.
F2 These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F3 Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV.
F4 Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F5 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members.
F6 Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV.
F7 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV") to its partners pursuant to a Rule 10b5-1 trading plan.
F8 These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F9 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners pursuant to a Rule 10b5-1 trading plan.
F10 These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F11 Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
F12 Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F13 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners pursuant to a Rule 10b5-1 trading plan.
F14 These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F15 Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
F16 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") to its partners pursuant to a Rule 10b5-1 trading plan.
F17 These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F18 Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA.
F19 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members.
F20 Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.
F21 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC CAN") to its partners pursuant to a Rule 10b5-1 trading plan.
F22 These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
F23 Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN.
F24 Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
F25 Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners.
F26 Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN.
F27 The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F28 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $145.89 to $145.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (28) to this Form 4.
F29 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $146.00 to $146.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (29) to this Form 4.
F30 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $147.01 to $147.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (30) to this Form 4.
F31 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $148.00 to $148.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (31) to this Form 4.
F32 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $149.00 to $149.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (32) to this Form 4.
F33 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (33) to this Form 4.
F34 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (34) to this Form 4.
F35 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.03 to $152.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (35) to this Form 4.

Remarks:

2/2: Since there are more than 30 rows associated with the applicable transactions and EDGAR will not allow for the entry of more than 30 rows on a single Form 4, this Form 4 is being filed in conjunction with a second Form 4 by the Reporting Person. The two Form 4s filed by the Reporting Person on the date hereof should be read together as one consolidated filing.